Revance Therapeutics, Inc. – NASDAQ:RVNC
Revance Therapeutics stock price today
$3.65
+0.58
+19.28%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 1 hour
Revance Therapeutics stock price monthly change
-14.52%
month
Revance Therapeutics stock price quarterly change
-14.52%
quarter
Revance Therapeutics stock price yearly change
-65.89%
year
Revance Therapeutics key metrics
Market Cap | 320.99M |
Enterprise value | 2.82B |
P/E | -6.37 |
EV/Sales | 21.31 |
EV/EBITDA | -9.17 |
Price/Sales | 18.97 |
Price/Book | 199.68 |
PEG ratio | 0.36 |
EPS | -3.63 |
Revenue | 236.64M |
EBITDA | -196.32M |
Income | -317.34M |
Revenue Q/Q | 5.28% |
Revenue Y/Y | 51.08% |
Profit margin | -268.87% |
Oper. margin | -257.95% |
Gross margin | 65.01% |
EBIT margin | -257.95% |
EBITDA margin | -82.96% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeRevance Therapeutics stock price history
Revance Therapeutics stock forecast
Revance Therapeutics financial statements
| Jun 2023 | 58.13M | -67.31M | -115.8% |
|---|---|---|---|
| Sep 2023 | 56.77M | -141.17M | -248.65% |
| Dec 2023 | 69.79M | -55.69M | -79.8% |
| Mar 2024 | 51.93M | -53.15M | -102.34% |
| Mar 2024 | 51.93M | -53.15M | -102.34% |
|---|---|---|---|
| Sep 2025 | 99.96M | -13.85M | -13.86% |
| Oct 2025 | 100.67M | -9.00M | -8.95% |
| Dec 2025 | 114.68M | -5.78M | -5.05% |
Analysts Price target
Financials & Ratios estimates
| 2023-02-28 | -1.822 | -1.82 |
|---|
| Jun 2023 | 597535000 | 570.74M | 95.52% |
|---|---|---|---|
| Sep 2023 | 532487000 | 638.68M | 119.94% |
| Dec 2023 | 478454000 | 630.05M | 131.69% |
| Mar 2024 | 508119000 | 606.79M | 119.42% |
| Jun 2023 | -53.38M | -39.53M | 97.47M |
|---|---|---|---|
| Sep 2023 | -50.96M | 51.58M | 37.46M |
| Dec 2023 | -42.73M | 2.37M | -1.62M |
| Mar 2024 | -65.93M | -31.70M | 92.82M |
Revance Therapeutics alternative data
| Aug 2023 | 534 |
|---|---|
| Sep 2023 | 534 |
| Oct 2023 | 534 |
| Nov 2023 | 534 |
| Dec 2023 | 534 |
| Jan 2024 | 534 |
| Feb 2024 | 534 |
| Mar 2024 | 597 |
| Apr 2024 | 597 |
| May 2024 | 597 |
| Jun 2024 | 597 |
| Jul 2024 | 597 |
Revance Therapeutics other data
80.91%
+2.73%
of RVNC is owned by hedge funds
150
+2
54.61M
+1.62M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2024 | 0 | 3908 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | HOLLANDER DAVID officer: CMO & Global Therapeut.. | Common Stock | 3,908 | $4.17 | $16,296 | ||
Sale | MOXIE DWIGHT officer: SVP, GC .. | Common Stock | 11,000 | $17.06 | $187,704 | ||
Sale | MOXIE DWIGHT officer: SVP, GC .. | Common Stock | 23,853 | $17.81 | $424,917 | ||
Sale | FOLEY MARK J director, officer.. | Common Stock | 26,279 | $22.57 | $593,143 | ||
Sale | SCHILKE TOBIN officer: CFO | Common Stock | 1,701 | $25.04 | $42,593 | ||
Sale | FOLEY MARK J director, officer.. | Common Stock | 26,279 | $24.94 | $655,346 | ||
Option | KOLAJA CAREY OCONNOR director | Common Stock | 2,500 | $18.12 | $45,300 | ||
Sale | KOLAJA CAREY OCONNOR director | Common Stock | 2,500 | $28.24 | $70,600 | ||
Option | KOLAJA CAREY OCONNOR director | Stock Option (Right to buy) | 2,500 | $18.12 | $45,300 | ||
Sale | SJUTS DUSTIN S officer: President | Common Stock | 5,000 | $30.82 | $154,095 |
| Patent |
|---|
Application Filling date: 9 Dec 2021 Issue date: 31 Mar 2022 |
Application Injectable Botulinum Toxin Formulations And Methods Of Use Thereof Having Long Duration Of Therapeutic Or Cosmetic Effect Filling date: 10 Sep 2021 Issue date: 3 Mar 2022 |
Application Filling date: 18 May 2021 Issue date: 28 Oct 2021 |
Application Filling date: 19 Apr 2021 Issue date: 7 Oct 2021 |
Application Filling date: 24 Feb 2021 Issue date: 16 Sep 2021 |
Application Filling date: 28 Dec 2020 Issue date: 19 Aug 2021 |
Application METHODS AND KITS FOR TOPICAL APPLICATION, REMOVAL, AND INACTIVATION OF THERAPEUTIC OR COSMETIC TOXIN COMPOSITIONS Filling date: 7 Dec 2020 Issue date: 24 Jun 2021 |
Application Filling date: 28 Aug 2018 Issue date: 3 Jun 2021 |
Application Filling date: 20 Nov 2020 Issue date: 11 Mar 2021 |
Application BOTULINUM TOXIN FORMULATIONS AND METHODS OF USE THEREOF IN PLANTAR FASCITIS WITH EXTENDED DURATION OF EFFECT Filling date: 5 Nov 2018 Issue date: 17 Dec 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 29 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
Revance Therapeutics: Impressive Sales Growth/Concerning Cash Burn
AbbVie Vs. AstraZeneca: Battle Of The Pharmaceutical Behemoths
Revance Therapeutics: PDUFA Catalyst 2023 And Increased Revenues
Evolus: Botox Copy Cat In A Challenging Aesthetic Market
Revance Therapeutics: Rally Seems Due For A Pause
Evolus: Extra Strength Dose Data Provides Additional Offering Expansion For Jeuveau
AbbVie: Why The Company Is Still Overvalued
Carpe Diem, Daxxify: Revance Therapeutic Preps For An Exciting Year
Revance Therapeutics: FDA Approval Of Daxxify Only One Part Of The Journey
-
What's the price of Revance Therapeutics stock today?
One share of Revance Therapeutics stock can currently be purchased for approximately $3.65.
-
When is Revance Therapeutics's next earnings date?
Unfortunately, Revance Therapeutics's (RVNC) next earnings date is currently unknown.
-
Does Revance Therapeutics pay dividends?
No, Revance Therapeutics does not pay dividends.
-
How much money does Revance Therapeutics make?
Revance Therapeutics has a market capitalization of 320.99M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 76.55% to 234.04M US dollars. Revance Therapeutics made a loss 323.99M US dollars in net income (profit) last year or -$1.82 on an earnings per share basis.
-
What is Revance Therapeutics's stock symbol?
Revance Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "RVNC".
-
What is Revance Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Revance Therapeutics?
Shares of Revance Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Revance Therapeutics's key executives?
Revance Therapeutics's management team includes the following people:
- Mr. Mark J. Foley Chief Executive Officer & Director(age: 60, pay: $986,590)
- Dr. Abhay Joshi Chief Operating Officer, Pres of R&D and Product Operations(age: 62, pay: $740,070)
- Mr. Dwight Moxie Senior Vice President, Gen. Counsel & Corporation Sec.(age: 48, pay: $630,890)
- Mr. Dustin S. Sjuts Pres(age: 46, pay: $622,260)
- Mr. Tobin C. Schilke Chief Financial Officer & Principal Accounting Officer(age: 50, pay: $576,090)
-
How many employees does Revance Therapeutics have?
As Jul 2024, Revance Therapeutics employs 597 workers.
-
When Revance Therapeutics went public?
Revance Therapeutics, Inc. is publicly traded company for more then 11 years since IPO on 6 Feb 2014.
-
What is Revance Therapeutics's official website?
The official website for Revance Therapeutics is revance.com.
-
Where are Revance Therapeutics's headquarters?
Revance Therapeutics is headquartered at 1222 Demonbreun Street, Nashville, TN.
-
How can i contact Revance Therapeutics?
Revance Therapeutics's mailing address is 1222 Demonbreun Street, Nashville, TN and company can be reached via phone at +61 57247755.
Revance Therapeutics company profile:
Revance Therapeutics, Inc.
revance.comExchange:
NASDAQ
Full time employees:
597
Industry:
Biotechnology
Sector:
Healthcare
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
1222 Demonbreun Street
Nashville, TN 37203
Nashville, TN 37203
CIK: 0001479290
ISIN: US7613301099
CUSIP: 761330109
